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ABSTRACT  
Objective: The primary objective was to assess the long-term 
safety of repeated courses of epratuzumab therapy in patients 
with moderate-to-severe systemic lupus erythematosus. Secondary 
objectives were to assess long-term efficacy and health-related 
quality of life (HRQoL). 
Methods: Eligible patients from the 12-week, phase IIb, 
randomized, placebo-controlled EMBLEM™ study (NCT00624351) 
enrolled into the open-label extension (OLE) study, SL0008 
(NCT00660881). In SL0008, patients received 1200 mg 
epratuzumab infusions at Weeks 0 and 2 of repeating 12-week 
cycles, plus standard of care. Safety measures included treatment-
emergent adverse events (TEAEs) and serious TEAEs. Efficacy 
measures included combined treatment response, BILAG score, 
SLEDAI score, physician’s and patient’s global assessment of 
disease activity. Total daily corticosteroid dose and HRQoL (SF-36) 
were also assessed. 
Results: 113 of the 203 patients who entered SL0008 (55.7%) 
continued epratuzumab therapy until study closure (total cumulative 
exposure: 381.3 patient-years; median exposure: 845 days; 
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maximum exposure: 1185 days/approximately 3.2 years). TEAEs 
were reported in 192 patients (94.6%), most commonly infections 
and infestations (68.0%; 138 patients). Serious TEAEs were 
reported in 51 patients (25.1%); 14 (6.9%) serious infections. In 
patients treated for 108 weeks (n=116), median corticosteroid dose 
was reduced from 10.0 mg/day at OLE screening to 5.0 mg/day 
at Week 108. Improvements in efficacy and HRQoL measures in 
EMBLEM™ were maintained in the OLE, while placebo patients 
exhibited similar improvements in disease activity upon switch to 
epratuzumab. 
Conclusion: Open-label epratuzumab treatment was well-tolerated 
for up to 3.2 years, and associated with sustained improvements 
in disease activity and HRQoL, while steroids were reduced. 
Abstract word count: 250 
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SIGNIFICANCE & INNOVATIONS 
• Epratuzumab is the first CD22-targeting monoclonal antibody 
in development for the treatment of moderate-to-severe SLE. 
• The results from this open-label extension study show that 
epratuzumab treatment in addition to standard of care was 
well-tolerated for up to 3.2 years with no new safety 
concerns identified. 
• Patients who had received epratuzumab therapy in the prior 
double-blind study maintained their initial improvements in 
disease activity, and placebo patients exhibited similar 
improvements in disease activity following switch to 
epratuzumab. 
• In patients receiving epratuzumab therapy for 108 weeks, 
median corticosteroid dose was halved from baseline. 
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Systemic lupus erythematosus (SLE) is a chronic autoimmune 
disease that can cause widespread tissue damage, particularly 
affecting musculoskeletal, mucocutaneous and renal systems.1, 2 
Since disease progression varies considerably between patients, 
SLE can be a challenging condition to manage.  
The goal of treatment for active moderate-to-severe SLE is to 
control inflammation and prevent organ damage. Corticosteroids are 
almost universally effective and are a cornerstone of treatment, 
however serious long-term complications are associated with their 
use.3, 4 Over the last 50 years, understanding of SLE 
pathogenesis has greatly increased and facilitated the development 
of therapies that target key immune cells and mediators in SLE. 
B cells have been recognized to play a critical role in SLE and 
are therefore an attractive target for new therapeutic agents.5, 6 
Currently only one such agent, belimumab, is licensed for use in 
moderate-to-severe SLE in the USA and Europe, which inhibits 
the biological activity of soluble B lymphocyte stimulator (BLyS).7, 8 
Epratuzumab is a novel B cell modulator. It is a monoclonal 
antibody that binds CD22, a co-receptor of the B cell receptor 
(BCR).9 The biology of CD22 is complex, but there is evidence 
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that epratuzumab binding induces colocalization of CD22 with the 
BCR, independent of BCR engagement. This promotes the 
inhibitory function of CD22 on BCR-mediated signaling and thereby 
modulates B cell activity with inhibition of B cell activation, but 
without total B cell depletion.9-14 The loss of BCR proteins from 
the B cell surface by mechanisms such as internalization and 
trogocytosis may further disrupt BCR activation.10, 13 Recent studies 
have suggested that the antibody may regulate the balance 
between regulatory IL-10 and pro-inflammatory cytokines in favor 
of the former through enhanced IL-10 expression and inhibition of 
pro-inflammatory IL-6 and TNF-α cytokine production.15, 16 B cell 
hyperactivity and altered cytokine production play a pivotal role in 
active SLE,17 ergo there is a strong rationale for targeting CD22-
mediated B cell signaling in SLE. 
The safety and efficacy of epratuzumab have been assessed in 
the ALLEVIATE-1 and -2 randomized controlled trials (RCTs; 
NCT00111306 and NCT00383214, respectively), and in the phase 
IIb EMBLEM™ study (NCT00624351). Although the ALLEVIATE 
trials were terminated early due to interruptions in medication 
supply, at Week 12 a higher proportion of patients receiving 360 
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mg/m2 epratuzumab achieved a British Isles Lupus Assessment 
Group (BILAG) response compared to patients receiving either 
placebo or 720 mg/m2 epratuzumab.18 No aberrant safety signals 
were identified.18 Epratuzumab-treated patients also reported greater 
improvements in HRQoL than those receiving placebo.19  
In EMBLEM™, a 12-week dose-ranging RCT, epratuzumab 
treatment was associated with clinically meaningful improvements in 
disease activity in moderate-to-severe SLE patients, with no new 
safety signals observed (EMBLEM™ was not powered to detect 
statistically significant improvements between treatment arms).14 
Eligible patients entered the EMBLEM™ open-label extension (OLE) 
study, SL0008 (NCT00660881), and continued receiving 
epratuzumab therapy. Here, we report the results from this OLE 
study on the safety and clinical outcomes observed in patients 
receiving epratuzumab for up to 3.2 years.  
METHODS 
Study design 
Entry criteria and design of the EMBLEM™ study have been 
published previously.14 Briefly, the phase IIb double-blind, placebo-
controlled, 12-week study enrolled adult (≥18 years) patients with 
Page 10 of 57
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
10 
 
active SLE who were positive for anti-nuclear antibody at 
screening and had received corticosteroids at a stable dose of 5–
60 mg/day (prednisone equivalent) for ≥5 days before the first dose 
of study medication. Enrolled patients had moderate-to-severe SLE, 
demonstrated by a Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI-2K)20 score of ≥6, and either BILAG-2004 index21 A 
grade (severe) disease activity in ≥1 body system (except renal 
or central nervous system), or BILAG B grade (moderate) disease 
activity in ≥2 body systems. At least one of the BILAG A grades, 
or ≥2 of the BILAG B grades must have been in the 
mucocutaneous, musculoskeletal or cardiorespiratory BILAG-2004 
index domains. 
In EMBLEM™, patients were randomized to receive placebo or 
one of 5 epratuzumab dosing regimens (100 mg every other 
week [Q2W], 400 mg Q2W, 1200 mg Q2W, 1800 mg Q2W or 
600 mg weekly [QW]) plus standard of care, with infusions 
delivered over the first 4 weeks of the 12-week study (Figure 1). 
Patients who completed the RCT or who discontinued blinded 
treatment due to lack of efficacy but completed ≥8 weeks of the 
RCT, were eligible to enter the OLE study, SL0008. SL0008 
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consisted of repeating 12-week treatment cycles (1200 mg infusion 
at Weeks 0 and 2; Figure 1) plus standard of care. The study 
was terminated early to consolidate the ongoing open-label 
extension studies from the EMBLEM™ and ALLEVIATE trials: 
patients had the option to enroll into another ongoing phase III 
long-term extension study, SL0012 (NCT01408576). Here we report 
results from the EMBLEM™ OLE study. 
The SL0008 study protocol was reviewed by an independent 
ethics committee or institutional review board for each site and 
was conducted in accordance with International Conference on 
Harmonization (ICH) Good Clinical Practice requirements and local 
laws. All patients gave their informed written consent before taking 
part. 
Safety assessments and analyses 
The primary objective of SL0008 was to assess the safety of 
repeated courses of epratuzumab therapy (1200 mg at Weeks 0 
and 2) given in 12-week treatment cycles (maximum exposure of 
1185 days/approximately 3.2 years; median exposure 845 
days/approximately 2.3 years). Analyses were performed on the 
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safety population, defined as all patients who had received at 
least 1 dose (or partial dose) of epratuzumab. Safety measures 
included treatment-emergent adverse events (TEAEs) and serious 
TEAEs classified by system organ class (SOC) and preferred term 
(PT) according to Medical Dictionary for Regulatory Activities 
(MedDRA) v.15.0. TEAEs occurring in ≥5% of patients by PT, 
and serious TEAEs occurring in ≥1.5% of patients by SOC and 
PT, as well as exposure-adjusted incidences, are reported. 
Discontinuations due to TEAEs are presented by MedDRA SOC 
and PT. 
A TEAE was classified as serious if it resulted in death, was 
life-threatening, required inpatient hospitalization or prolongation of 
an existing hospitalization, resulted in persistent or significant 
disability/incapacity or was a congenital anomaly or birth defect. 
Additionally, any important medical event that may not have been 
life-threatening or resulted in death or hospitalization could be 
classified as serious if, based on appropriate medical judgment, it 
may have jeopardized the patient or required medical or surgical 
intervention to prevent one of the other outcomes. Pregnancies 
were dated and reported from the last menstrual period.  
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Efficacy and HRQoL evaluations 
The secondary objectives of SL0008 were to assess efficacy and 
changes in SLE disease activity and HRQoL assessed by Medical 
Outcomes Short-Form (SF-36) survey with prolonged epratuzumab 
treatment. Efficacy variables assessed included BILAG improvement 
without worsening, combined treatment response, BILAG score 
(BILAG-2004 Index),21 SLEDAI-2K score20 and physician’s and 
patient’s global assessment of disease activity (PGA and PtGA; 
100 mm visual analogue scale).  
Treatment response in this study was based on a modified 
version of the BILAG-based Composite Lupus Assessment (BICLA) 
composite endpoint,22 and was defined as BILAG improvement 
without worsening, and no worsening in SLEDAI-2K or PGA. The 
fourth criterion of BICLA, “no treatment failure,” was not included. 
BILAG improvement without worsening was defined as all A 
scores at baseline improved to B/C/D, and all B scores improved 
to C/D, with no worsening in other BILAG organ systems such 
that there were no new A scores and ≤1 new B score. No 
worsening in PGA was defined as less than 10% worsening. 
Efficacy variables were captured at EMBLEM™ baseline and OLE 
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screening, at 4-week intervals through Week 48, then at 12-week 
intervals and at the last study visit. Total daily corticosteroid dose 
was summarized at 4-week intervals throughout and converted to 
prednisone equivalent prior to analysis.  
HRQoL was measured using the SF-36. Assessments were carried 
out at EMBLEM™ baseline and SL0008 screening in all 
randomized EMBLEM™ patients, and at 12-week intervals during 
the study and at the last study visit in the SL0008 safety 
population. Minimum clinically important differences were defined as 
≥2.5-point increases from EMBLEM™ baseline for physical 
component summary (PCS) and mental component summary 
(MCS) scores and ≥5.0 points in domain scores where increases 
in scores signal improvement.23-26  
Statistical analysis  
The safety population was analyzed using SAS® (SAS Institute, 
Version 9.1.3 Service Pack 4, Cary, NC, USA). Summary statistics 
are presented. No inferential analyses were conducted. Sample 
size was not determined on the basis of formal statistical 
calculations, as the primary objective of this study was to 
continue to evaluate safety in eligible patients from EMBLEM™. 
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Missing components of combined treatment response were imputed 
using last observation carried forward for a maximum of one visit, 
and thereafter treated as missing. Missing values of SF-36 domain 
scores were imputed using last observation carried forward from 
EMBLEM™ baseline to SL0008 screening. All other observed data 
are reported with no imputation of missing data.  
Comparisons to both EMBLEM™ baseline and SL0008 screening 
are reported for efficacy and HRQoL evaluations. Changes from 
baseline are reported as changes from EMBLEM™ baseline in 
those patients included in SL0008. Data are presented to Week 
108: the last time-point at which >50% of patients reported data 
for combined treatment response, and are also presented for the 
last visit, giving the last available value for each patient 
regardless of when the last visit occurred. 
RESULTS   
Patient disposition and baseline characteristics 
Of the 203 patients who entered SL0008, 113 (55.7%) continued 
epratuzumab infusion until study closure (Figure 1) and 90 
patients (44.3%) withdrew from the study. The most common 
reasons for withdrawal were TEAEs (29 patients; 14.3%; of which 
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7 were pregnancies), withdrawal of consent (25 patients; 12.3%), 
lack of efficacy (23 patients; 11.3%) and loss of efficacy (5 
patients; 2.5%). Withdrawals over time are shown in 
Supplementary Figure 1. One death occurred during the study, 
which was deemed unlikely to be related to the study drug 
(discussed below).  
Patient characteristics and demographics at the start of SL0008 
are summarized in Table 1. Patients receiving concomitant 
medications for SLE included corticosteroids (191 patients; 94.1%), 
immunosuppressives (90 patients; 44.3%) and antimalarials (88 
patients; 43.3%) (Table 1). 
Exposure to epratuzumab 
Total cumulative exposure to epratuzumab across both EMBLEM™ 
and SL0008 was 381.3 patient-years; median duration of 
epratuzumab exposure in SL0008 was 845 days (range: 75–1185 
days), approximately 2.3 years median and 3.2 years maximum 
exposure.  
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Summary of adverse events 
During SL0008, TEAEs were reported in 192 patients (94.6%), the 
majority of which were mild or moderate in intensity; 51 patients 
(25.1%) had severe TEAEs (Table 2). Over the study period, 
TEAEs in 87 patients (42.9%) were assessed as related to the 
drug (Table 2) and 29 patients (14.3%) withdrew due to TEAEs; 
commonest causes were lupus nephritis (6 patients; 3.0%) and 
SLE flare (5 patients; 2.5%). 
Summaries of all TEAEs with an incidence of at least 5% in the 
safety population by MedDRA SOC and PT are provided in Table 
3. The most common TEAEs reported by SOC were infections 
and infestations (68.0%), and the most common TEAEs by PT 
included urinary tract infection (24.6%), upper respiratory tract 
infection (23.2%), headache (19.7%), sinusitis (10.8%), and nausea 
and asthenia (9.9% each; Table 3). 
Serious TEAEs with an incidence of at least 1.5% in the safety 
population by MedDRA SOC and PT are provided in Table 4. A 
total of 98 serious TEAEs were reported in 57 patients (28.1%). 
The most commonly reported serious TEAE by SOC were 
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infections and infestations (14 patients; 6.9%) discussed further 
below. The most common serious TEAEs reported by PT were 
SLE flares (7 patients; 3.4%), followed by lupus nephritis (4 
patients; 2.0%) and symptomatic cholelithiasis (3 patients; 1.5%). 
One death, which was considered unrelated to the study drug by 
the investigator, occurred during the study; a postmenopausal 43-
year-old Caucasian female with a past medical history of 
osteoporosis and hypertension experienced a serious TEAE with 
echocardiographic signs of pericarditis 43 days after the most 
recent infusion of epratuzumab and 57 days after the first 
infusion. Although the patient first recovered, her condition 
worsened dramatically shortly after discharge and she subsequently 
died. The cause of death was considered high-grade chronic heart 
failure. 
Adverse events considered of particular interest 
Infections 
The most commonly reported infections were urinary tract infection 
(50 patients, 24.6%), upper respiratory tract infection (47 patients; 
23.2%) and sinusitis (22 patients; 10.8%) (Table 3). Although 14 
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patients reported serious infections, most were single cases in 
individual patients; the only serious infections reported in more 
than one patient were gastroenteritis, sepsis and urosepsis (2 
patients each; 1% each). There were no reported events of 
pneumonia, Herpes zoster or tuberculosis and only one reported 
event of Clostridium difficile colitis. 
Neoplasms 
Neoplasms (benign, malignant or unspecified) were reported in 3 
patients during the study. These included thyroid neoplasm in 2 
patients (small nodules on the thyroid in one, and tiny bilateral 
hypoechoic thyroid nodules in the other) and basal cell carcinoma, 
breast cancer, and malignant lip neoplasm (stage unspecified) in 
a single patient. 
Lupus nephritis 
Lupus nephritis developed in 7 patients (3.4%), 4 of which were 
classified as serious TEAEs (one was confirmed by biopsy). Six 
of the patients discontinued the study; but one patient continued 
the study, despite nephritis being classified as serious. Only one 
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patient had a prior history of renal disease, with previously 
confirmed membranous lupus glomerulonephritis class V.  
Pregnancies 
Seven women (3.4%) became pregnant over the course of the 
study, discontinued epratuzumab and withdrew from the study. Of 
these patients, 2 delivered healthy full-term babies, 2 underwent 
induced terminations, one miscarried (suspected ectopic pregnancy 
8 weeks after receiving the last dose of epratuzumab, which 
miscarried at 47 days gestation) and 2 delivered premature babies 
at 32 weeks gestation. One of these patients became pregnant 2 
days after receiving the last dose of epratuzumab, was 
hospitalized due to SLE at 30 weeks gestation, and underwent a 
cesarean section due to preeclampsia. The baby died 2 weeks 
after delivery due to an unconfirmed pulmonary hemorrhage. The 
other became pregnant 13 days after receiving the last dose of 
epratuzumab, had an early cesarean section despite no reported 
pregnancy complication and delivered a healthy baby.  
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Corticosteroid use 
Median corticosteroid dose was 10.0 mg/day (range: 0.0–60.0 
mg/day) at both EMBLEM™ baseline and SL0008 screening, which 
was decreased to 5.0 mg/day (range: 0.0–40.0 mg/day) in the 
patients remaining in the study at Week 108 of the OLE (Figure 
2A). The proportion of patients requiring corticosteroid doses of 
>17.5 mg/day decreased from 28.6% at EMBLEM™ baseline and 
21.2% at SL0008 screening to 12.1% at Week 108 
(Supplementary Figure 2). Conversely, the proportion of patients 
receiving >0.0–5.0 mg/day increased from 27.6% at EMBLEM™ 
baseline and 26.1% at SL0008 screening to 39.7% at Week 108, 
and the proportion of patients not receiving any corticosteroids 
also increased from 2.0% at EMBLEM™ baseline and 5.9% at 
SL0008 screening to 12.1% at Week 108 (Supplementary Figure 
2).  
These are observed data, so may be affected by patient 
discontinuation. Thus the corticosteroid dose at the last visit for 
each patient was analyzed regardless of the time that this 
occurred. At the last visit, the median corticosteroid dose was 
10.0 mg/day (Figure 2A), the same as at SL0008 entry. However, 
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the proportion of patients requiring a dose ≤7.5 mg/day increased, 
and the proportion taking >7.5 mg/day decreased compared to 
EMBLEM™ baseline (Supplementary Figure 2).   
To assess corticosteroid-sparing effects in those who remained in 
the study to Week 108 (n=116), a separate analysis was 
performed. Median corticosteroid dose at EMBLEM™ baseline and 
at SL0008 screening in these patients was 10.0 mg/day (range: 
0.0–50.0 mg/day). At Week 48 of the OLE, median corticosteroid 
dose had decreased to 5.5 mg/day (range: 0.0–40.0 mg/day) in 
these patients and remained stable to 5.0 mg (range: 0.0–40.0 
mg/day) at Week 108.  
Efficacy endpoints  
During SL0008, the observed percentage of patients with BILAG 
improvement without worsening, compared to EMBLEM™ baseline, 
increased over time from 34.5% at SL0008 screening to 63.8% at 
Week 108. At their last visit, regardless of when this occurred, 
BILAG improvement without worsening was seen in 48.3% of 
patients. 
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The percentage of patients achieving a combined treatment 
response (defined as BILAG improvement without worsening, and 
no worsening in SLEDAI or PGA) increased during SL0008. This 
was most pronounced in EMBLEM™ placebo patients (Figure 2B) 
who exhibited responses comparable to those who received active 
treatment in the EMBLEM™ trial. Response rates increased from 
25.7% at SL0008 screening to 45.7% at the last visit in those 
patients who had originally received placebo during EMBLEM™, 
and from 33.9% at SL0008 screening to 40.7% in those who 
received epratuzumab in EMBLEM™.  
Median total BILAG score of the treated population decreased 
from EMBLEM™ baseline and remained stable throughout SL0008 
(Figure 2C). At the last visit, the median total BILAG score was 
10.0 (range: 0–72), compared to 14.0 (range: 0–57) at SL0008 
screening. In patients who remained in the study at Week 108, 
the median total BILAG score was 9.0; a decrease of 64% from 
the median total BILAG score of all patients at EMBLEM™ 
baseline.  
The proportion of patients who improved from maximum BILAG 
system grades A or B at EMBLEM™ baseline to BILAG grades C 
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or D at Week 108 of SL0008 exceeded 60% in the 
musculoskeletal, mucocutaneous, cardiorespiratory, constitutional and 
renal domains (observed data, Supplementary Figure 3). 
Median SLEDAI score also decreased from EMBLEM™ baseline to 
Week 108 of SL0008 (Figure 2D). At the last visit for each 
patient, the median total SLEDAI score was lower than that at 
SL0008 screening (last visit: 8.0 [range: 0–32]; OLE screening: 
10.0 [range: 0–34]). At Week 108, approximately two thirds of 
patients remaining in the study had at least a 4- or 6-point 
improvement in SLEDAI compared to EMBLEM™ baseline 
(Supplementary Table 1). Improvements in SLEDAI of at least 8 
points were seen in 46.8% of patients at Week 108 and, at the 
last visit, in 39.7% of patients (Supplementary Table 1).  
Both PGA and PtGA improved (Supplementary Table 1). A 
decrease from EMBLEM™ baseline was observed in median PGA 
score until Week 48 of SL0008, and remained stable through 
Week 108. Median PGA score at the last visit was 25.0 (range: 
0–94), 50% less than EMBLEM™ baseline (50.0, range: 0–90). 
Similarly, median PtGA scores improved from 53.0 (range: 1–90) 
at EMBLEM™ baseline to 41.0 (range: 0–95) at SL0008 screening, 
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and continued to improve during SL0008 to 34.0 (range: 1–81) at 
Week 108. At the last visit for each patient, median PtGA score 
was similar to that at SL0008 entry (40.0, range: 1–97). Physician 
assessment seemed to correspond with the patients’ assessment 
of their disease; median changes from baseline in PGA and 
PtGA at the last visit were -23.0 (range: -65–57) and -9.0 (range: 
-75–96), respectively. 
HRQoL 
Mean SF-36 PCS and MCS scores increased from SL0008 
screening to Week 48, and were maintained to Week 108 
(Supplementary Figure 4A). Change from EMBLEM™ baseline in 
PCS and MCS were clinically meaningful (≥2.5 points) at all time 
points measured up to Week 108. At Week 108, the percentage 
of those with a clinically meaningful improvement from EMBLEM™ 
baseline in PCS and MSC was 70.8% and 59.3% of patients, 
respectively. At the last visit for each patient, 61.9% achieved 
clinically meaningful changes in PCS, and 44.1% achieved 
clinically meaningful changes in MCS. 
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Increases from EMBLEM™ baseline in all SF-36 domain scores 
were observed at SL0008 screening in all patient groups, 
including those who received placebo in EMBLEM™. SF-36 domain 
scores were further increased with clinically meaningful changes 
from baseline to Week 48, and maintained or further improved up 
to Week 108, indicating improved HRQoL (Supplementary Figure 
4B).  
DISCUSSION 
In this open-label extension study, SLE patients received 
epratuzumab for a median of 2.3 years (maximum 3.2 years), 
giving a total exposure of more than 380 patient-years. No new 
safety signals were identified, and the one death that was 
reported (due to chronic heart failure) was deemed by the 
investigator as unlikely to be related to the study drug. Serious 
infections and infestations were reported in 14 patients (6.9%), 
with no incidences of pneumonia, Herpes zoster or any cases of 
tuberculosis. 
The improvements in disease activity seen in EMBLEM™ were 
maintained through the OLE. This was seen in multiple individual 
Page 27 of 57
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
27 
 
BILAG organ systems, and by SLEDAI (assessed by reduction in 
median score and increasing proportion of patients with significant 
reductions of SLEDAI score), as well as PGA, demonstrating 
breadth of response. Patients who had received placebo in 
EMBLEM™ also exhibited rapid improvements in disease activity 
following a switch to epratuzumab treatment at SL0008 entry, as 
measured by combined treatment response, consistent with the 
response in epratuzumab-treated patients in EMBLEM™.14 Most 
patients who continued receiving epratuzumab therapy throughout 
the study were able to reduce their dose of concomitant 
corticosteroids, while maintaining reductions in BILAG score.  
During SL0008, 5 patients (2.5%) withdrew due to loss of 
efficacy, and 23 (11.3%) due to lack of efficacy. Those whose 
withdrawal was attributed to TEAEs of lupus flare (2.5%) or 
nephritis (3.0%) should also be considered non-responsive to the 
treatment. The remainder withdrew due to other TEAEs, withdrawal 
of consent, protocol violation or other reasons.  
In the 55.7% of patients who remained on treatment in the OLE, 
clinically meaningful improvements in PtGA and HRQoL observed 
in EMBLEM™27 were sustained long-term (up to 3.2 years). 
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Although discordance in physician and patient global assessments 
of disease activity has been previously observed in SLE (a 
difference of ≥25 mm on a 0–100 mm scale is considered 
clinically meaningful),28 here there was concordance between 
patients’ and physicians’ assessments of disease activity, indicated 
by median PtGA and PGA scores, and similarly shown by 
HRQoL and the specific lupus disease activity indices. 
This study was not without limitation: sources of bias, imputation 
methods, comparison group, validated questionnaires and the size 
of the study population are discussed. The potential bias 
introduced by patient dropout is inherent in the open-label design 
of this study, since discontinuation due to lack of efficacy could 
positively skew observed results. Patient retention in this study 
was 55.7% at the time of study closure. Inclusion of data from 
the last visit, giving the last available value for each patient 
regardless of when the last visit occurred, can give some 
perspective on the impact of dropout bias. Here, conservative 
imputation methods were used; the only missing data imputed 
were individual components of combined treatment response, which 
were carried forward a maximum of one visit, and missing values 
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of SF-36 domain scores, which were carried forward from 
EMBLEM™ baseline to SL0008 screening only. Additionally, in a 
study in which all patients receive study drug, no comparisons 
are available with patients treated with community standard of 
care without epratuzumab. Validated patient-reported outcomes 
(PROs) specific to lupus such as LupusPRO, Lupus Impact 
Tracker (LIT) and LupusQoL were not available when the study 
was initiated,29-31 and may have provided further insight into 
HRQoL. The results of phase III trials, utilizing larger patient 
cohorts, will provide further important safety information, given that 
there were relatively small numbers in this OLE study. 
Open-label epratuzumab treatment was found to be well-tolerated 
with extended use up to 3.2 years, giving a total patient 
exposure of over 380 patient-years. At the time of study closure, 
55.7% of patients were still receiving epratuzumab therapy. In 
those receiving epratuzumab for 108 weeks, the median 
corticosteroid dose was reduced from 10.0 mg/day at EMBLEM™ 
baseline and SL0008 screening to 5.0 mg/day. Improvements in 
efficacy and HRQoL seen in EMBLEM™ were maintained over the 
duration of the SL0008 study. These results strongly support the 
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continued study of epratuzumab for the treatment of patients with 
moderate-to-severe SLE.  
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TABLES AND FIGURES 
TABLES 
Table 1. Patient demographics and characteristics at the start of 
SL0008 
 Safety population (n=203) 
Age, years, mean (SD) 38.7 (11.0) 
Female, n (%) 192 (94.6) 
Ethnic group  
White, n (%) 158 (77.8) 
Black, n (%) 20 (9.9) 
Asian, n (%) 22 (10.8) 
Other/mixed, n (%) 3 (1.5) 
Immunosuppressives, n (%) 90 (44.3) 
Antimalarials, n (%) 88 (43.3) 
Corticosteroids (prednisone equivalent), n (%) 191 (94.1) 
Dose, median mg/day (range) 10.0 (0–60) 
None, n (%) 12 (5.9) 
>0–5.0 mg/day, n (%) 53 (26.1) 
>5.0–7.5 mg/day, n (%) 15 (7.4) 
>7.5–12.5 mg/day, n (%) 64 (31.5) 
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>12.5–17.5 mg/day, n (%) 16 (7.9) 
>17.5 mg/day, n (%) 43 (21.2) 
Total BILAG score,* median (min, max) 14.0 (0, 57) 
Total SLEDAI score, median (min, max) 10.0 (0, 34) 
PGA (100 mm VAS),† median (min, max) 31.0 (0, 96) 
PtGA (100 mm VAS),† median (min, max) 41.0 (0, 95) 
*Total BILAG score was calculated according to the BILAG-2004 
index convention: A=12, B=8, C=1, D=0, E=0. BILAG grades were 
determined for all 9 body systems by independent central readers. 
†Assessed on a scale of 0 (very good, asymptomatic, and no 
limitation of normal activities), to 100 (very poor, very severe 
symptoms which are intolerable, and inability to carry out all 
normal activities). The safety population consisted of all patients 
who received at least 1 dose (or partial dose) of study 
medication. BILAG: British Isles Lupus Assessment Group; PGA: 
Physician’s Global Assessment of Disease Activity; PtGA: Patient’s 
Global Assessment of Disease Activity; SD: Standard Deviation; 
SLE: Systemic Lupus Erythematosus; SLEDAI: Systemic Lupus 
Erythematosus Disease Activity Index; VAS: Visual Analogue Scale. 
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Table 2. Summary of TEAEs during SL0008 
 
Safety population (n=203) 
         Patients, n Patients, % 
Number of 
events 
Any TEAE 192 94.6 1946 
Severe TEAEs 51 25.1 88 
Discontinuations due to TEAEs 29 14.3 35 
Drug-related TEAEs* 87 42.9 300 
Serious TEAEs 57 28.1 98 
Infusion reactions 29 14.3 74 
Deaths† 1 0.5 1 
The safety population consisted of all patients who received at least 1 
dose (or partial dose) of epratuzumab. *TEAEs considered possibly, 
probably, or definitely related to the study drug by the investigator; †One 
death which was considered as unlikely to be related to the study drug 
by the investigator. TEAE: treatment-emergent adverse event. 
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Table 3. TEAEs occurring in ≥5% of patients by preferred term 
during SL0008 
MedDRA v15.0 System 
Organ Class 
Safety population (n=203) 
Preferred Term 
Patients, 
n 
Patients, 
% 
No. of 
events 
Incidence 
rate/100 
patient-years 
Any TEAE 192 94.6 1946 510.4 
Blood and lymphatic system 
disorders 
40 19.7 65 17.0 
Iron deficiency anaemia 12 5.9 15 3.9 
Cardiac disorders 20 9.9 29 7.6 
Tachycardia 13 6.4 16 4.2 
Ear and labyrinth disorders 15 7.4 18 4.7 
Vertigo 12 5.9 14 3.7 
Gastrointestinal disorders 64 31.5 199 52.2 
Nausea 20 9.9 30 7.9 
Vomiting 18 8.9 22 5.8 
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Diarrhoea 17 8.4 29 7.6 
General disorders and 
administration site conditions 
63 31.0 150 39.3 
Asthenia 20 9.9 36 9.4 
Pyrexia 14 6.9 29 7.6 
Oedema peripheral 14 6.9 17 4.5 
Fatigue 13 6.4 15 3.9 
Infections and infestations 138 68.0 487 127.7 
Upper respiratory tract 
infection 
47 23.2 93 24.4 
Urinary tract infection 50 24.6 87 22.8 
Sinusitis 22 10.8 30 7.9 
Nasopharyngitis 16 7.9 18 4.7 
Bronchitis 18 8.9 23 6.0 
Gastroenteritis 11 5.4 13 3.4 
Viral infections 11 5.4 13 3.4 
Musculoskeletal and 
connective tissue disorders 
77 37.9 170 44.6 
Systemic lupus 17 8.4 20 5.2 
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erythematosus 
Arthralgia 16 7.9 24 6.3 
Back pain 14 6.9 25 6.6 
Nervous system disorders 79 38.9 154 40.4 
Headache 40 19.7 66 17.3 
Dizziness 19 9.4 24 6.3 
Psychiatric disorders 36 17.7 59 15.5 
Depression 16 7.9 18 4.7 
Anxiety 14 6.9 16 4.2 
Respiratory, thoracic and 
mediastinal disorders 
53 26.1 101 26.5 
Dyspnoea 15 7.4 20 5.2 
Cough 13 6.4 14 3.7 
Oropharyngeal pain 11 5.4 13 3.4 
Skin and subcutaneous tissue 
disorders 
54 26.6 100 26.2 
Rash 15 7.4 22 5.8 
Vascular disorders 38 18.7 52 13.6 
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Hypertension 18 8.9 20 5.2 
The safety population consisted of all patients who received at 
least 1 dose (or partial dose) of epratuzumab. 
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Table 4. Serious TEAEs occurring in ≥1.5% of patients by system 
organ class and preferred term during SL0008 
MedDRA v15.0 System 
Organ Class 
Safety population (n=203) 
Preferred Term 
Patients, 
n 
Patients, 
% 
No. of 
events 
Incidence 
rate/100 
patient-years 
Any serious TEAE 57 28.1 98 25.7 
Blood and lymphatic system 
disorders 
5 2.5 5 1.3 
Gastrointestinal disorders 3 1.5 16 4.2 
General disorders and 
administration site conditions 
3 1.5 3 0.8 
Hepatobiliary disorders 3 1.5 3 0.8 
Cholelithiasis 3 1.5 3 0.8 
Infections and infestations 14 6.9 15 3.9 
Injury, poisoning and procedural 
complications 
3 1.5 3 0.8 
Musculoskeletal and connective 11 5.4 14 3.7 
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tissue disorders 
Systemic lupus 
erythematosus 
7 3.4 7 1.8 
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
3 1.5 6 1.6 
Nervous system disorders 3 1.5 3 0.8 
Psychiatric disorders 4 2.0 4 1.0 
Renal and urinary disorders 7 3.4 7 1.8 
Lupus nephritis 4 2.0 4 1.0 
Vascular disorders 5 2.5 6 1.6 
The safety population consisted of all patients who received at 
least 1 dose (or partial dose) of epratuzumab. 
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FIGURE LEGENDS 
Figure 1. EMBLEM™ and SL0008 study design and patient 
disposition 
cd: cumulative dose; IV: intravenous; OLE: open-label extension; 
QW: every week; Q2W: every other week; RCT: randomized 
controlled trial; SOC: standard of care; TEAE: treatment-emergent 
adverse event. 
Figure 2. Clinical efficacy of epratuzumab during SL0008: A) 
Median corticosteroid dose, B) Combined treatment response, C) 
Median total BILAG score,* D) Median total SLEDAI score 
*Total BILAG score was calculated according to the BILAG-2004 
index convention: A=12, B=8, C=1, D=0, E=0. BILAG grades were 
determined for all 9 body systems by independent central readers. 
Treatment response in this study was based on a modification of 
the BILAG-based Composite Lupus Assessment (BICLA) composite 
endpoint, defined as BILAG improvement without worsening, and 
no worsening in SLEDAI-2K or PGA; the fourth criteria of BICLA 
(“no treatment failure”) was not included. Last visit: last available 
value for each patient during the EMLBEM™ OLE, regardless of 
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time of discontinuation. BILAG: British Isles Lupus Assessment 
Group; OLE: Open-label Extension; SLEDAI: Systemic Lupus 
Erythematosus Disease Activity Index. 
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week; RCT: randomized controlled trial; SOC: standard of care; TEAE: treatment-emergent adverse event.  
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Clinical efficacy of epratuzumab during SL0008: A) Median corticosteroid dose, B) Combined treatment 
response, C) Median total BILAG score,* D) Median total SLEDAI score  
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